Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases

被引：47
|
作者：
Guan, Shi-Yang [1 ,2 ]
Leng, Rui-Xue [1 ,2 ]
Khan, Muhammad Imran [1 ,2 ]
Qureshi, Humera [1 ,2 ]
Li, Xiang-Pei [3 ]
Ye, Dong-Qing [1 ,2 ]
Pan, Hai-Feng [1 ,2 ]
机构：
[1] Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China
[2] Anhui Med Univ, Anhui Prov Lab Populat Hlth & Major Dis Screening, 81 Meishan Rd, Hefei, Anhui, Peoples R China
[3] Anhui Prov Hosp, Dept Rheumatol & Immunol, 17 Lujiang Rd, Hefei, Anhui, Peoples R China
来源：
INFLAMMATION | 2017年 / 40卷 / 01期
基金：
中国国家自然科学基金;
关键词：
interleukin-35; Th17; cells; Treg cells; therapeutic agent; autoimmune diseases; REGULATORY T-CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; MESENCHYMAL STEM-CELLS; B-CELLS; TH17/TREG IMBALANCE; INDUCED ARTHRITIS; IMMUNE-RESPONSES; MURINE MODEL; IL-35; CYTOKINE;
D O I：
10.1007/s10753-016-0453-9
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Autoimmune diseases contain a large number of pathologies characterized by various factors that contribute to a breakdown in self-tolerance. Cytokine-mediated immunity plays an essential role in the pathogenesis of varieties of autoimmune diseases. Recent studies reveal that interleukin-35 (IL-35), a newly identified cytokine of IL-12 family, is implicated in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), etc. In this review, we will discuss the biological features of IL-35 and summarize recent advances in the role of IL-35 in the development and pathogenesis of autoimmune diseases; the discoveries gained from these findings might translate into future therapies for these diseases.
引用
收藏
页码：303 / 310
页数：8
相关论文
共 50 条
  • [41] Interleukin-35 expression is associated with colon cancer progression
    Zhang, Jian
    Mao, Tao
    Wang, Shuyun
    Wang, Dongsheng
    Niu, Zhaojian
    Sun, Zhenqing
    Zhang, Jianli
    ONCOTARGET, 2017, 8 (42) : 71563 - 71573
  • [42] Different expression levels of interleukin-35 in asthma phenotypes
    Wei Li
    Ruihan Gao
    Tong Xin
    Peng Gao
    Respiratory Research, 21
  • [43] Rapid Communication: Plasma Interleukin-35 in Children with Autism
    Rose, Destanie
    Ashwood, Paul
    BRAIN SCIENCES, 2019, 9 (07)
  • [44] The Immunobiology of Interleukin-35 and Its Regulation and Gene Expression
    Song, Mei
    Ma, Xiaojing
    REGULATION OF CYTOKINE GENE EXPRESSION IN IMMUNITY AND DISEASES, 2016, 941 : 213 - 225
  • [45] Interleukin-35 Limits Anti-Tumor Immunity
    Tumis, Meghan E.
    Sawant, Deepali V.
    Szymczak-Workman, Andrea L.
    Andrews, Lawrence P.
    Delgoffe, Greg M.
    Yano, Hiroshi
    Beres, Amy J.
    Vogel, Peter
    Workman, Creg J.
    Vignali, Dario A. A.
    IMMUNITY, 2016, 44 (02) : 316 - 329
  • [46] Interleukin-35: A key player managing pre-diabetes and chronic inflammatory type 1 autoimmune diabetes
    Chakraborty, Ratul
    Mukherjee, Ashis Kumar
    Bala, Asis
    WORLD JOURNAL OF DIABETES, 2024, 15 (10)
  • [47] Analysis of serum interleukin-10 and interleukin-35 levels In pemphigoid patients
    Kabuto, M.
    Fujimoto, N.
    Takahashi, T.
    Tanaka, T.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S91 - S91
  • [48] The immunoexpression of interleukin-35 in muscle biopsies of idiopathic inflammatory myopathies
    Zamecnik, J.
    Hacek, J.
    Dahmen, R. A.
    Mann, H.
    Vencovsky, J.
    HISTOPATHOLOGY, 2012, 61 : 183 - 183
  • [49] Interleukin-35 pathobiology in periodontal disease: a systematic scoping review
    Patrick R. Schmidlin
    Mandana Dehghannejad
    Omid Fakheran
    BMC Oral Health, 21
  • [50] Pterostilbene: a potential therapeutic agent for fibrotic diseases
    Wenhong Wang
    Ke Li
    Dandan Bai
    Jiabin Wu
    Weihua Xiao
    Inflammopharmacology, 2024, 32 : 975 - 989
12345